Insider Sale: Chief Medical Officer of $DNLI (DNLI) Sells 2,907 Shares

Quiver QuantitativeJan 8 20:31 ET

Denali Therapeutics Receives FDA Breakthrough Therapy Designation For Tividenofusp Alfa In Treatment Of Hunter Syndrome (MPS II)

BenzingaJan 8 08:01 ET

Express News | Denali Therapeutics Inc - Expects to Submit Bla for Tividenofusp Alfa in Early 2025

ReutersJan 8 08:00 ET

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

GlobeNewswireJan 8 08:00 ET

Denali Therapeutics Is Maintained at Overweight by JP Morgan

Dow JonesJan 7 14:20 ET · Ratings

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

Zacks Jan 7 13:30 ET